Investment
Features
FeesSafety
Academy
More
Pluang+

Compare D R Horton Inc (DHI) vs Medpace Holdings Inc (MEDP) Price & Performance

D R Horton IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

D R Horton Inc vs Medpace Holdings Inc — how do they compare? D R Horton Inc trades at $150.79 (market cap $42.18B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: D R Horton Inc is far larger — about 2.5× Medpace Holdings Inc's market cap, and D R Horton Inc pays a 1.19% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

DHIMEDP
Market Cap
$42.18B$16.90B
Sector
Consumer CyclicalTechnology
52-Week High
$184.04$620.59
52-Week Low
$132.53$393.42
Enterprise Value
$47.28B$16.52B
Dividend Yield
1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

D R Horton Inc

DHI trades at $146.49, down slightly by 0.12% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $3.20, beating estimates, but revenue guidance for FY2026 was lowered. Valuation ratios appear reasonable with a P/E of 14.37 and P/S of 1.31. Operating cash flow remains strong at $3.42B for 2025, though net cash flow was negative due to significant financing outflows.

The outlook is mixed; disciplined execution supports margins, but weak housing demand and elevated mortgage rates pose headwinds. Analyst consensus is a Buy with a $153 target, offering modest upside. Key risks include persistent affordability pressures and competitive threats from disruptors like Boxabl.

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About D R Horton Inc

D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.

Read more on DHI

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP